Amiodarone Dosing Regimen
For life-threatening arrhythmias, administer IV amiodarone as a 150-mg bolus over 10 minutes, followed by 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours (total ~1000 mg/24 hours), before transitioning to oral therapy with 800-1600 mg/day in divided doses until 10 g total is given, then maintain at 200-400 mg/day. 1, 2
Intravenous Dosing
Acute Loading (First 24 Hours)
- Initial bolus: 150 mg IV over 10 minutes for life-threatening arrhythmias 1, 2
- Repeat bolus: May repeat 150 mg over 10-30 minutes if necessary for breakthrough VF or hemodynamically unstable VT 1, 2
- Maintenance infusion: 1 mg/min for 6 hours (360 mg), then 0.5 mg/min for 18 hours (540 mg) 1, 2
- Total first 24 hours: Approximately 1000 mg 2
Ongoing IV Maintenance
- Standard rate: 0.5 mg/min (720 mg/24 hours) after initial loading 2
- Duration: Can continue for 2-3 weeks regardless of age, renal function, or left ventricular function 2
- Maximum initial rate: Do not exceed 30 mg/min 2
- Concentration limits: Use ≤2 mg/mL for peripheral lines; concentrations >2 mg/mL require central venous catheter 2
Critical Safety Considerations for IV Administration
- Must use volumetric infusion pump (drop counters can underdose by up to 30%) 2
- Administer through central line when possible with in-line filter 2
- Risk of hepatocellular necrosis and acute renal failure with higher concentrations and faster rates than recommended 2
- Monitor for hypotension, bradycardia, and AV block during IV administration 1, 2
Oral Dosing
Loading Phase
The oral loading regimen varies by indication:
For ventricular arrhythmias:
- 800-1600 mg/day in divided doses until 10 g total cumulative dose achieved 1
- Typically requires 2-4 weeks to reach steady state 3
For atrial fibrillation:
- 600-800 mg/day in divided doses until 10 g total cumulative dose achieved 1
- May use higher initial dosing or IV loading in unstable inpatients 1
Maintenance Phase
- Standard maintenance: 200-400 mg/day for ventricular arrhythmias 1
- Atrial fibrillation maintenance: 200 mg/day 1
- Use lowest effective dose to minimize toxicity risk 1
Transition from IV to Oral
The oral dose depends on duration of IV therapy 1, 2:
- IV <1 week: Start 800-1600 mg/day oral 1
- IV 1-3 weeks: Start 600-800 mg/day oral 1
- IV >3 weeks: Start 400 mg/day oral 1, 2
Clinical monitoring is essential during transition, particularly in elderly patients 2. Studies show that providing 2-4 hours of IV/oral overlap does not reduce breakthrough arrhythmias compared to no overlap 4, suggesting immediate transition is reasonable once rate control is achieved.
Important Clinical Considerations
Monitoring Requirements
- Adverse effects are dose-dependent and related to total cumulative exposure 1
- Most serious toxicity: Pulmonary toxicity (cough, dyspnea, interstitial infiltrates) 1
- Other major toxicities: Thyroid dysfunction, hepatotoxicity, corneal deposits, photosensitivity, neurologic effects 1, 5, 6
- Long-term monitoring required even after discontinuation due to prolonged half-life (14-58 days) 7, 8
Efficacy Considerations
- Serum concentrations <1.0 mg/L associated with relapse in responders 3
- Concentrations >2.5 mg/L associated with increased CNS and GI side effects 3
- Onset of action: IV effects occur in <30 minutes; oral loading typically requires 2-4 weeks for optimal control 1, 3
- Combined IV/oral loading shortens time to control (20 vs 105 days) and reduces cumulative dose needed (10 vs 48 g) 9
Drug Interactions
- Warfarin: Requires dose adjustment 6
- Statins: Interactions with simvastatin and atorvastatin 6
- Avoid grapefruit juice with oral therapy (inhibits CYP3A metabolism) 2